

# Raf1 (Ser296) Antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP22271a

## Product Information

---

<b>Application</b>	WB, E
<b>Primary Accession</b>	<a href="#">P04049</a>
<b>Other Accession</b>	<a href="#">Q99N57</a> , <a href="#">Q5R5M7</a> , <a href="#">P11345</a>
<b>Reactivity</b>	Human, Rat, Mouse
<b>Predicted</b>	Mouse, Rat
<b>Host</b>	Rabbit
<b>Clonality</b>	polyclonal
<b>Isotype</b>	Rabbit IgG
<b>Clone Names</b>	RB56636
<b>Calculated MW</b>	73052

## Additional Information

---

<b>Gene ID</b>	5894
<b>Other Names</b>	RAF proto-oncogene serine/threonine-protein kinase, 2.7.11.1, Proto-oncogene c-RAF, cRaf, Raf-1, RAF1, RAF
<b>Target/Specificity</b>	This Raf1 (Ser296) antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 268-301 amino acids from the human Raf1.
<b>Dilution</b>	WB~~1:2000 E~~Use at an assay dependent concentration.
<b>Format</b>	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
<b>Storage</b>	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
<b>Precautions</b>	Raf1 (Ser296) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

## Protein Information

---

<b>Name</b>	RAF1 ( <a href="#">HGNC:9829</a> )
<b>Synonyms</b>	RAF
<b>Function</b>	Serine/threonine-protein kinase that acts as a regulatory link between the

membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF- $\kappa$ B activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation.

#### Cellular Location

Cytoplasm. Cell membrane. Mitochondrion. Nucleus. Note=Colocalizes with RGS14 and BRAF in both the cytoplasm and membranes. Phosphorylation at Ser-259 impairs its membrane accumulation. Recruited to the cell membrane by the active Ras protein Phosphorylation at Ser-338 and Ser-339 by PAK1 is required for its mitochondrial localization. Retinoic acid-induced Ser-621 phosphorylated form of RAF1 is predominantly localized at the nucleus

#### Tissue Location

In skeletal muscle, isoform 1 is more abundant than isoform 2.

## Background

Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2- antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF- $\kappa$ B activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation.


## References

Bonner T.I.,et al.Nucleic Acids Res. 14:1009-1015(1986).  
Ota T.,et al.Nat. Genet. 36:40-45(2004).

Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.  
Bonner T.I.,et al.Mol. Cell. Biol. 5:1400-1407(1985).  
Andreu-Perez P.,et al.Sci. Signal. 4:RA58-RA58(2011).

## Images

---



Anti-Raf1 (Ser296) Antibody at 1:2000 dilution + MCF-7 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 73 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.